Illustration of a heart with malfunctioning signaling pathways, symbolizing type 2 diabetes impact.

Decoding Diabetes: How Type 2 Alters Heart Function

Theo Raines in Health & Wellness December 2025 • 4 min read.

"New Research Reveals Changes in Heart Muscle Phosphorylation, Offers Hope for Improved Treatments"

For individuals with type 2 diabetes, managing blood sugar is only part of the battle. The condition inflicts a cascade of effects throughout the body, including the cardiovascular system. Understanding how diabetes alters heart function is crucial for developing effective treatments and preventative strategies.

Nitric oxide (NO) plays a vital role in maintaining healthy blood vessels and cardiovascular function. The enzyme endothelial nitric oxide synthase (eNOS) is responsible for producing NO. When eNOS isn't working correctly, it can lead to a host of cardiovascular problems. Recent research is shedding light on how diabetes disrupts eNOS function in heart muscle.

A new study published in the Journal of Applied Physiology investigated how type 2 diabetes affects eNOS activity in the heart. The researchers focused on a process called phosphorylation, which acts like a switch, turning eNOS activity up or down. Their findings reveal specific changes in phosphorylation patterns in the hearts of individuals with type 2 diabetes, offering potential targets for future therapies.

eNOS Phosphorylation: What's Changed in Diabetic Hearts?

Illustration of a heart with malfunctioning signaling pathways, symbolizing type 2 diabetes impact.

The study compared heart tissue samples from individuals with and without type 2 diabetes. Researchers examined eNOS phosphorylation at several key sites, including Ser1177, Thr495, Ser635, and Ser114. The results showed significant differences in phosphorylation patterns between the two groups.

Here’s a breakdown of the key findings:

Ser1177: Phosphorylation at this site, which increases eNOS activity, was significantly decreased in the diabetic group.
Akt: Phosphorylation of Akt, a protein kinase involved in eNOS activation, was also decreased in the diabetic group.
Thr495: Similar to Ser1177 and Akt, phosphorylation at Thr495 which reduces eNOS activity, was decreased.
Ser635: Interestingly, phosphorylation at Ser635, another site that increases eNOS activity, was significantly increased in the diabetic group.
Ser114: No significant difference was observed in phosphorylation at this site between the two groups.

These changes suggest that type 2 diabetes disrupts the normal regulation of eNOS activity in the heart. The decreased phosphorylation at Ser1177 and Akt, coupled with increased phosphorylation at Ser635, indicates a complex interplay of factors affecting NO production.

The Road Ahead: New Avenues for Treatment

This research opens new doors for understanding and treating cardiovascular complications associated with type 2 diabetes. By targeting specific phosphorylation sites on eNOS, researchers may be able to develop therapies that restore normal NO production in the heart, ultimately improving heart function and overall health for individuals with diabetes. Further studies are needed to fully elucidate the mechanisms involved and to translate these findings into clinical applications.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

Everything You Need To Know

What is the primary focus of the new research regarding type 2 diabetes and the heart?

The primary focus is on understanding how type 2 diabetes affects heart muscle function at a molecular level. Specifically, the research investigates changes in the phosphorylation patterns of endothelial nitric oxide synthase (eNOS), an enzyme crucial for producing nitric oxide (NO), which is vital for healthy blood vessels and cardiovascular function. The study aims to identify potential targets for future therapies by analyzing these changes.

How does type 2 diabetes disrupt eNOS function in the heart, according to the study?

The study reveals that type 2 diabetes disrupts the normal regulation of eNOS activity through alterations in phosphorylation patterns. The research highlights decreased phosphorylation at Ser1177 and Akt, both of which are associated with increasing eNOS activity. Conversely, increased phosphorylation at Ser635 was observed, also linked to increased eNOS activity. These combined changes suggest a complex interplay that affects NO production in the heart. The alterations in the phosphorylation of eNOS at specific sites like Thr495 and Ser114 also contribute to the overall disruption.

What are the implications of the changes in eNOS phosphorylation sites like Ser1177, Akt, and Ser635 in the context of type 2 diabetes?

The changes in eNOS phosphorylation at these sites have significant implications for heart function in individuals with type 2 diabetes. Decreased phosphorylation at Ser1177 and Akt likely reduces eNOS activity, leading to lower NO production. Because NO is vital for maintaining healthy blood vessels and cardiovascular function, this reduction can contribute to cardiovascular problems. The increased phosphorylation at Ser635, though also associated with increased eNOS activity, might not fully compensate for the other negative changes. This imbalance can lead to impaired heart function and potentially increase the risk of cardiovascular complications associated with diabetes.

How might this research on eNOS phosphorylation lead to new treatments for cardiovascular complications related to type 2 diabetes?

This research opens new avenues for treatment by identifying specific phosphorylation sites on eNOS that are disrupted in individuals with type 2 diabetes. By targeting these sites, researchers may be able to develop therapies that restore normal NO production in the heart. For example, therapies could aim to increase phosphorylation at Ser1177 and Akt, which would enhance eNOS activity, or modulate phosphorylation at Ser635. These interventions could improve heart function and overall cardiovascular health for people with diabetes. Further studies are needed to translate these findings into clinical applications.

Can you explain the roles of key molecules and processes mentioned, like eNOS, NO, phosphorylation, Akt, Ser1177, Thr495, Ser635, and Ser114, in the context of this diabetes research?

In this research, eNOS (endothelial nitric oxide synthase) is an enzyme responsible for producing NO (nitric oxide), which is essential for healthy blood vessels and cardiovascular function. Phosphorylation is a process where a phosphate group is added to a molecule, acting like a switch to turn eNOS activity up or down at specific sites. Akt is a protein kinase involved in eNOS activation. Ser1177, Thr495, Ser635, and Ser114 are specific sites on eNOS where phosphorylation occurs. The study found that in individuals with type 2 diabetes, phosphorylation at Ser1177 and Akt was decreased, reducing eNOS activity, while phosphorylation at Ser635 was increased. Thr495 also showed alterations. These changes in phosphorylation patterns disrupt the normal regulation of eNOS activity, impacting NO production and potentially contributing to cardiovascular complications associated with diabetes.